PSP Peripheral Immune Dysfunction

PSP Peripheral Immune Dysfunction

Overview

Peripheral immune dysfunction represents a critical yet underappreciated component of [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy) (PSP) pathogenesis. While the central nervous system hallmarks of PSP (4R-tau aggregation, neuronal loss, neuroinflammation) are well-characterized, accumulating evidence demonstrates significant peripheral immune system alterations that may contribute to disease progression, provide diagnostic biomarkers, and offer therapeutic targets. The peripheral immune system communicates bidirectionally with the brain through multiple pathways—cellular trafficking, cytokine signaling, neural pathways, and glymphatic system modulation—making peripheral immune dysfunction a potentially modifiable target for intervention[@picillo2026][@massaro2024].

Peripheral Immune Cell Alterations

Natural Killer (NK) Cells

The NKscape Study (2026) represents a landmark investigation revealing significant natural killer (NK) cell alterations in PSP patients[@picillo2026]. This comprehensive characterization of NK cell populations identified several key findings:

PSP Peripheral Immune Dysfunction

Overview

Peripheral immune dysfunction represents a critical yet underappreciated component of [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy) (PSP) pathogenesis. While the central nervous system hallmarks of PSP (4R-tau aggregation, neuronal loss, neuroinflammation) are well-characterized, accumulating evidence demonstrates significant peripheral immune system alterations that may contribute to disease progression, provide diagnostic biomarkers, and offer therapeutic targets. The peripheral immune system communicates bidirectionally with the brain through multiple pathways—cellular trafficking, cytokine signaling, neural pathways, and glymphatic system modulation—making peripheral immune dysfunction a potentially modifiable target for intervention[@picillo2026][@massaro2024].

Peripheral Immune Cell Alterations

Natural Killer (NK) Cells

The NKscape Study (2026) represents a landmark investigation revealing significant natural killer (NK) cell alterations in PSP patients[@picillo2026]. This comprehensive characterization of NK cell populations identified several key findings:

• CD56bright NK cell reduction: Significant reduction in CD56bright NK cells in PSP patients compared to healthy controls and disease comparators
• Functional impairment: NK cells from PSP patients show reduced cytotoxic activity and interferon-gamma (IFN-γ) production capacity
• Phenotypic shifts: Altered expression of activating and inhibitory receptors including NKG2D, NKp46, and CD158b
• Disease correlation: NK cell alterations correlate with disease severity scores (PSPRS) and disease duration
• Potential link to peripheral immune surveillance disruption: Impaired NK cell function may allow persistence of pathological stimuli or dysregulated immune cell populations

Monocyte and Macrophage Alterations

Peripheral monocytes in PSP show altered phenotypes and functions[@massaro2024][@bar2024]:

• CD14++CD16+ intermediate monocyte expansion: This pro-inflammatory monocyte subset is significantly increased in PSP patients
• Monocyte activation markers: Elevated expression of HLA-DR, CD86, and toll-like receptor 4 (TLR4) on monocytes from PSP patients
• Cytokine production: Increased production of pro-inflammatory cytokines including IL-6, TNF-α, and IL-1β upon stimulation
• Transmigration potential: Altered expression of matrix metalloproteinases (MMPs) may facilitate monocyte trafficking across the blood-brain barrier
• May contribute to neuroinflammation through peripheral-central immune interaction: Monocytes can migrate to the CNS and differentiate into macrophages, potentially propagating inflammatory signals

The monocyte alterations in PSP appear distinct from other neurodegenerative conditions, potentially offering diagnostic discrimination from Parkinson's disease and Alzheimer's disease.

T Lymphocyte Abnormalities

T lymphocyte alterations provide insight into adaptive immune involvement in PSP[@hall2023]:

• CD8+ T cell changes: Altered CD8+ T cell populations with increased exhausted phenotypes (PD-1+, TIM-3+)
• CD4+ T cell shifts: Reduced regulatory T cell (Treg) numbers and function in PSP
• T cell cytokine profiles: Impaired T cell cytokine production capacity
• Autoimmune associations: Some studies report associations between PSP and autoimmune conditions
• Potential antigen-driven responses: Evidence for antigen-specific T cell responses to tau or neuronal antigens in some patients

The T cell abnormalities suggest that adaptive immune mechanisms may contribute to PSP pathogenesis, though the specific antigens driving these responses remain largely unidentified.

B Cell and Antibody Findings

B cell alterations and autoantibody findings in PSP include:

• Elevated B cell activating factor (BAFF): Increased BAFF levels in PSP patients may reflect ongoing B cell activation
• Autoantibody profiles: Some studies report increased autoantibodies against neuronal antigens in PSP
• Potential for antigen presentation: B cells may serve as antigen-presenting cells and influence T cell responses
• Therapeutic implications: B cell-targeted therapies have been proposed for PSP based on these findings

Cytokine and Chemokine Profiles

Pro-inflammatory Cytokines

Systemic inflammatory markers in PSP show characteristic patterns[@ruganzu2024][@pikkarainen2024]:

| Cytokine | Direction | Clinical Relevance |
|----------|-----------|-------------------|
| IL-6 | Elevated | Correlates with disease progression |
| TNF-α | Elevated | Associated with cognitive decline |
| IL-1β | Elevated/Variable | Links peripheral inflammation to CNS |
| IL-8 | Elevated | Associated with gait impairment |
| IFN-γ | Variable | May indicate immune activation |

CSF inflammatory marker profiling in PSP (2024) demonstrated elevated levels of IL-6, TNF-α, and CXCL10 compared to controls, with patterns distinct from AD and PD[@ruganzu2024]. The cytokine profile in PSP differs from Alzheimer's disease and Parkinson's disease, potentially providing diagnostic utility when combined with other biomarkers.

Chemokine Alterations

Chemokine alterations in PSP include[@kim2025]:

• CXCL10 (IP-10): Elevated in PSP plasma and CSF, associated with disease severity
• CCL2 (MCP-1): Variable levels; may facilitate monocyte recruitment
• CX3CL1 (Fractalkine): Altered; mediates neuron-microglial communication
• CCL11 (Eotaxin): Elevated in some PSP cohorts; associated with eosinophil recruitment

Anti-inflammatory Cytokines

Counter-regulatory mechanisms include:

• IL-10: Often reduced in PSP, limiting anti-inflammatory compensation
• TGF-β: Variable; may be increased in some patients but functionally impaired
• IL-1RA: Elevated in some patients but insufficient to control inflammation

Blood-Brain Barrier Communication

Peripheral-Central Immune Pathways

Multiple pathways mediate communication between peripheral immune changes and CNS pathology in PSP:

Blood-Brain Barrier Permeability

Evidence for BBB alterations in PSP includes:

• Increased BBB permeability: Some studies report increased CSF/serum albumin ratio suggesting mild BBB disruption
• Endothelial dysfunction: Markers of endothelial activation (VCAM-1, ICAM-1) are elevated in PSP
• Pericyte involvement: Pericyte coverage may be reduced, compromising BBB integrity
• Transport alterations: Changed expression of drug transporters (P-gp) on BBB endothelial cells

Clinical Implications

Diagnostic Biomarker Potential

Peripheral immune markers offer potential for PSP diagnosis[@smith2025]:

• Multi-marker panels: Combination of NK cell markers, cytokines, and neuronal-derived extracellular vesicles improves diagnostic accuracy to 85-90%
• Disease discrimination: Peripheral immune profiles differ from PD, MSA, and CBS, potentially aiding differential diagnosis
• Disease stage markers: Some markers correlate with disease severity and progression rate
• Therapeutic monitoring: Immune markers may serve as pharmacodynamic biomarkers for immunomodulatory therapies

Disease Progression Markers

Longitudinal studies suggest:

• Baseline immune profiles predict progression: Elevated pro-inflammatory markers at baseline correlate with faster progression
• Longitudinal changes: Some immune markers show characteristic changes over disease course
• Survival associations: Certain immune parameters correlate with survival duration in PSP

Therapeutic Implications

Peripheral immune targets include:

• Anti-inflammatory approaches: Minocycline and other anti-inflammatory agents have been trialed in PSP
• Immunomodulation: Targeting specific immune pathways (IL-6, TNF-α) may modify disease progression
• Peripheral-central axis modulation: Therapies targeting peripheral immune activation may indirectly benefit CNS pathology
• Cellular therapies: NK cell and monocyte modulation strategies are under investigation

Comparison with Other Tauopathies

While both are 4R tauopathies, neuroimmune profiles differ between PSP and CBS[@constantinides2024]:

• NK cell alterations: More pronounced in PSP compared to CBS
• Cytokine patterns: Different cytokine elevation patterns between PSP and CBS
• Monocyte phenotypes: Distinct monocyte phenotypic shifts
• Autoimmune associations: Variable between conditions

Cross-Disease Comparison Table

| Immune Parameter | PSP | CBS | CBD | AD |
|-----------------|-----|-----|-----|-----|
| NK cell reduction | Marked | Moderate | Mild | Moderate |
| CD14++CD16+ monocytes | Elevated | Elevated | Variable | Elevated |
| IL-6 in CSF | High | Moderate | Moderate | High |
| Treg reduction | Yes | Yes | Variable | Yes |
| CXCL10 elevation | High | Moderate | Moderate | Variable |

Research Directions

Emerging Biomarkers

• Neuron-derived extracellular vesicles (NDEVs): Plasma NDEVs positive for tau species show promise as PSP-specific biomarkers[@zheng2026]
• Exosomal tau: Tau-containing exosomes in blood may reflect CNS pathology
• Multi-omics integration: Combining genomic, proteomic, and metabolomic data from blood samples

Therapeutic Targets

• Peripheral immune modulation: Strategies targeting peripheral immune activation
• Monocyte trafficking: Inhibiting monocyte migration to CNS
• Cytokine blockade: IL-6, TNF-α, and other cytokine-targeting approaches
• Cellular therapies: NK cell and Treg-based therapies

Future Research Priorities

See Also

• [Neuroinflammation in PSP](/mechanisms/neuroinflammation-psp)
• [Blood-Brain Barrier in PSP](/mechanisms/psp-blood-brain-barrier)
• [CSF and Blood Biomarkers in PSP](/biomarkers/psp-fluid-biomarkers)
• [PSP Disease Progression Staging](/mechanisms/psp-disease-progression-staging)
• [TREM2 in Neurodegeneration](/mechanisms/trem2-microglial-activation)